BlinkLab reports AI‑driven ADHD detection tool achieves 82% sensitivity in European study

BlinkLab (ASX: BB1) announced positive results from a European clinical trial of its Dx2 AI‑driven, smartphone‑based diagnostic platform for attention‑deficit/hyperactivity disorder (ADHD). The study, conducted with Mental Care Group (MCG) across multiple centres in the Netherlands, enrolled 375 children aged six to 17, of which 208 were analysed after excluding participants on medication or with other neurodevelopmental conditions. Among the analysed cohort, 117 children had a confirmed ADHD diagnosis and 91 were neurotypical controls.

The Dx2 algorithm correctly identified ADHD in 82% of cases (sensitivity) and correctly classified 83% of the control group (specificity). The digital neurobehavioural biomarkers captured via brief smartphone assessments—such as blinking and facial reflexes—showed a positive association with clinical observations. BlinkLab’s CEO Dr Henk‑Jan Boele said the results provide the first evidence that such biomarkers can detect ADHD and highlighted the unmet medical need and larger addressable market compared with autism.

Following the trial, BlinkLab plans to pursue U.S. regulatory approval and conduct a comparable study in the United States, aiming to complement traditional ADHD assessment methods with objective, efficient digital tools.